Loading...
•
Mar 31, 2024
Kodiak Sciences Q1 2024 Earnings Report
Reported business highlights and financial results for the quarter ended March 31, 2024.
Key Takeaways
Kodiak Sciences reported a net loss of $43.0 million for the first quarter of 2024, with $245.9 million in cash and cash equivalents, which is expected to support operations into 2026. The company is advancing its clinical programs for tarcocimab, KSI-501, and KSI-101, with key milestones including the initiation of the DAYBREAK study and Phase 1b enrollment for the APEX study.
Made excellent operational progress with clinical programs for tarcocimab, KSI-501 and KSI-101.
Enrolling well in GLOW2 and remain on track to activate mid-year DAYBREAK study in wet AMD.
Expect to initiate Phase 1b enrollment in June for the APEX study of KSI-101 in patients with macular edema associated with inflammation.
Shared the advancement on growing repertoire of novel small molecules and biologics for the duet and triplet platforms at the ARVO 2024 Annual Meeting.
Forward Guidance
Kodiak Sciences believes that the current cash will support current and planned operations into 2026 and is focused on advancing its clinical programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...